Celcuity (NASDAQ:CELC – Get Free Report) had its price target upped by stock analysts at Craig Hallum from $20.00 to $25.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective suggests a potential upside of 15.05% from the company’s previous close.
Other analysts have also recently issued reports about the stock. Stifel Nicolaus started coverage on shares of Celcuity in a research report on Thursday, February 22nd. They set a “buy” rating and a $40.00 price target on the stock. Needham & Company LLC raised their price objective on shares of Celcuity from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a report on Thursday.
View Our Latest Analysis on CELC
Celcuity Trading Up 19.7 %
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Barclays PLC acquired a new position in Celcuity during the second quarter valued at approximately $37,000. Bank of America Corp DE grew its holdings in shares of Celcuity by 40.3% during the fourth quarter. Bank of America Corp DE now owns 3,159 shares of the company’s stock worth $44,000 after purchasing an additional 907 shares in the last quarter. BNP Paribas Arbitrage SNC increased its stake in Celcuity by 9,962.2% in the second quarter. BNP Paribas Arbitrage SNC now owns 4,528 shares of the company’s stock valued at $50,000 after acquiring an additional 4,483 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of Celcuity during the 2nd quarter valued at about $63,000. Finally, JPMorgan Chase & Co. bought a new stake in Celcuity in the fourth quarter worth $70,000. Institutional investors own 63.33% of the company’s stock.
About Celcuity
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
See Also
- Five stocks we like better than Celcuity
- What is the Shanghai Stock Exchange Composite Index?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Earnings Per Share Calculator: How to Calculate EPS
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.